Κατάλογος ενδεικτικών δημοσιεύσεων του τμήματος Ιατρικής ΑΠΘ σε διεθνή επιστημονικά περιοδικά κατά τα τελευταία 5 έτη.
Export 46 results:
Συντάκτης [ Τίτλος] Τύπος Έτος Φίλτρα: Συντάκτης is Karagiannis, Thomas [Clear All Filters]
Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis.
BMJ. k1310.
(2018). Artificial pancreas treatment for outpatients with type 1 diabetes: systematic review and meta-analysis..
BMJ. 361, k1310.
(2018). Association between response rates and survival outcomes in patients with newly diagnosed multiple myeloma. A systematic review and meta-regression analysis.
European Journal of Haematology. 98111125151171328622526459851317339343312102118301141312212432349259292117201512520158233100(6), 563 - 568.
(2017).
(2017). Burden and Coping Strategies of Hypoglycemia in People with Diabetes..
Curr Diabetes Rev.
(2023). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy.
Core Evidence. Volume 12, 1 - 10.
(2017). Canagliflozin in the treatment of type 2 diabetes: an evidence-based review of its place in therapy..
Core Evid. 12, 1-10.
(2017). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications.
Therapeutic Advances in Drug Safety. 7(2), 36 - 38.
(2016). Cardiovascular risk with DPP-4 inhibitors: latest evidence and clinical implications..
Ther Adv Drug Saf. 7(2), 36-8.
(2016). Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes..
Ann Intern Med. 174(1), 141.
(2021). Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis..
Ann Intern Med. 173(4), 278-286.
(2020). Comparative efficacy and safety of glucose-lowering drugs as adjunctive therapy for adults with type 1 diabetes: A systematic review and network meta-analysis..
Diabetes Obes Metab. 23(3), 822-831.
(2021).
(2023).
(2021).
(2012).
Effects of sodium-glucose co-transporter-2 inhibitors by background cardiovascular medications: A systematic review and meta-analysis..
Diabetes Obes Metab. 25(10), 3020-3029.
(2023). Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysis..
Diabetes Res Clin Pract. 193, 110144.
(2022). GLP-1 receptor agonists and SGLT2 inhibitors for older people with type 2 diabetes: A systematic review and meta-analysis..
Diabetes Res Clin Pract. 174, 108737.
(2021). GLP-1 receptor agonists for cardiovascular outcomes with and without metformin. A systematic review and meta-analysis of cardiovascular outcomes trials..
Diabetes Res Clin Pract. 177, 108921.
(2021).
(2020). In type 2 diabetes, weekly semaglutide reduced HbA 1c and increased weight loss more than weekly exenatide ER.
Annals of Internal Medicine. 168(8), JC46.
(2018). In type 2 diabetes, weekly semaglutide reduced HbA1c and increased weight loss more than weekly exenatide ER..
Ann Intern Med. 168(8), JC46.
(2018). KDIGO made 12 recommendations for managing diabetes with CKD..
Ann Intern Med. 174(3), JC26.
(2021). Management of type 2 diabetes in the new era..
Hormones (Athens). 22(4), 677-684.
(2023). Management of type 2 diabetes with the dual GIP/GLP-1 receptor agonist tirzepatide: a systematic review and meta-analysis..
Diabetologia. 65(8), 1251-1261.
(2022).